文献速递肿瘤 PET/CT核素与放射性配体治疗

不可切除III期非小细胞肺癌患者放化疗±度伐利尤单抗维持治疗中[18F]FDG PET/CT的代谢模式

Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-23

纳入43例不可切除III期非小细胞肺癌患者,均于标准放化疗前后行[18F]FDG PET/CT,其中16例在第二次PET/CT前开始度伐利尤单抗维持治疗。度伐利尤单抗组肿瘤摄取强度降幅更大(SUVmax中位下降-70.0% vs -24.8%,p=0.009),脾脏摄取升高(中位+12.5% vs -4.4%,p=0.029),提示免疫相关不良事件的发现更多(12/16 vs 8/27,p=0.005),总生存显著更长。

要点

  • 度伐利尤单抗维持组肿瘤SUVmax中位降幅-70.0%,单纯放化疗组-24.8%,p=0.009。
  • 度伐利尤单抗维持组脾脏摄取中位+12.5%,单纯放化疗组-4.4%,p=0.029。
  • 提示免疫相关不良事件的PET/CT发现:度伐利尤单抗组12/16 vs 单纯放化疗组8/27,p=0.005。

核心结论

  • 放化疗后度伐利尤单抗维持治疗导致肿瘤代谢变化方向不同,同时增加脾脏代谢,并较未用度伐利尤单抗者出现更高比例的提示免疫相关不良事件的发现。
  • 由于度伐利尤单抗显著延长生存,待更多临床事件出现后将结合代谢变化进一步充实生存分析。

研究设计与样本

  • 纳入43例不可切除III期非小细胞肺癌患者,均有标准放化疗前后两次[18F]FDG PET/CT。
  • 16/43例患者在第二次PET/CT前开始度伐利尤单抗维持治疗(CRT-IO),其余接受单纯放化疗(CRT)。
  • 比较CRT与CRT-IO的肿瘤部位及次级淋巴器官摄取,阅片者对度伐利尤单抗给药设盲并评估提示免疫相关不良事件的发现。

主要发现

  • 两组初始摄取特征相当。
  • 度伐利尤单抗组肿瘤摄取强度降幅显著高于单纯放化疗组,SUVmax中位下降-70.0% vs -24.8%,p=0.009。
  • 度伐利尤单抗组脾脏摄取升高而单纯放化疗组下降,中位+12.5% vs -4.4%,p=0.029。
  • 度伐利尤单抗组总生存显著长于单纯放化疗组,该组进展/死亡事件少。
  • 提示免疫相关不良事件的PET/CT发现在度伐利尤单抗组更常见(12/16 vs 8/27例,p=0.005)。

关键数值与推荐

  • 肿瘤SUVmax中位变化:CRT-IO组-70.0% vs CRT组-24.8%,p=0.009。
  • 脾脏摄取中位变化:CRT-IO组+12.5% vs CRT组-4.4%,p=0.029。
  • 提示免疫相关不良事件的PET/CT发现比例:CRT-IO组12/16 vs CRT组8/27,p=0.005。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 度伐利尤单抗组进展/死亡事件少,生存分析将在更多临床事件出现后结合代谢变化进一步充实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with unresectable stage III non-small-cell lung cancer (NSCLC), durvalumab maintenance treatment after chemoradiotherapy (CRT) significantly improves survival. So far, however, metabolic changes of tumoral lesions and secondary lymphoid organs under durvalumab are unknown. Hence, we assessed changes on [18F]FDG PET/CT in comparison to patients undergoing CRT alone. METHODS: Forty-three patients with [18F]FDG PET/CT both before and after standard CRT for unresectable stage III NSCLC were included, in 16/43 patients durvalumab maintenance treatment was initiated (CRT-IO) prior to the second PET/CT. Uptake of tumor sites and secondary lymphoid organs was compared between CRT and CRT-IO. Also, readers were blinded for durvalumab administration and reviewed scans for findings suspicious for immunotherapy-related adverse events (irAE). RESULTS: Initial uptake characteristics were comparable. However, under durvalumab, diverging metabolic patterns were noted: There was a significantly higher reduction of tumoral uptake intensity in CRT-IO compared to CRT, e.g. median decrease of SUVmax -70.0% vs. -24.8%, p = 0.009. In contrast, the spleen uptake increased in CRT-IO while it dropped in CRT (median + 12.5% vs. -4.4%, p = 0.029). Overall survival was significantly longer in CRT-IO compared to CRT with few events (progression/death) noted in CRT-IO. Findings suggestive of irAE were present on PET/CT more often in CRT-IO (12/16) compared to CRT (8/27 patients), p = 0.005. CONCLUSION: Durvalumab maintenance treatment after CRT leads to diverging tumoral metabolic changes, but also increases splenic metabolism and leads to a higher proportion of findings suggestive of irAE compared to patients without durvalumab. Due to significantly prolonged survival with durvalumab, survival analysis will be substantiated in correlation to metabolic changes as soon as more clinical events are present.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Holzgreve A, Taugner J, Käsmann L, et al. Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment. Eur J Nucl Med Mol Imaging. 2023. PMID: 36951991. doi:10.1007/s00259-023-06192-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。